CPIC 2026 | Innovations in Exosome Therapeutics Session
We look forward to exploring the path to industrialization of innovative exosome drugs with you.
Time：
2026-07-08 20:43
Author：
xieyijun
“The Third Way” in Biopharma Game Theory
Who Pays for Restricting Chinese Data?
Time：
2026-07-07 20:34
Author：
xieyijun
M&A Wave Returns: 52 Deals in Six Months, Chinese Presence Surges
Chinese innovative drugs are moving to center stage on the global platform.
Time：
2026-07-06 20:18
Author：
xieyijun
Major AI Model Giants Are Flocking into AI Drug Discovery
From exporting capabilities to owning assets.
Time：
2026-07-06 08:17
Author：
写意君
AZ Four Arrows Stone Medicine: MNC competes for early research in China
Reshaping Global Value Division
Time：
2026-07-04 08:18
Author：
xieyijun
Recommended content
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
The rise of self-immune big products
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务